FindTrial
Sign In

To Assess the Effectiveness of Preoperative Nebulized Dexmedetomidine in Reducing Postoperative Confusion in Older Adults Undergoing General Anesthesia

Evaluation Of Preoperative Nebulized Dexmedetomidine for the prevention of postoperative delirium in elderly patients undergoing surgery under general anesthesia - A Randomized Control Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/095648
Enrollment
180
Registered
2025-10-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Dexmedetomidine Nebulization: Nebulized Dexmedetomidine at a dose of 1 mcg/kg body weight, diluted in 4 ml normal saline, administered once over 10 minutes in the preoperative area, app

Sponsors

Academic Investigator Initiated study
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients consent to participate in the study. 2.Elderly patients of age more than 60 years. 3.Patients belonging to ASA 1,2, 3 4.Patients scheduled for elective surgeries under General Anesthesia.

Exclusion criteria

Exclusion criteria: 1.Allergic to dexmedetomidine. 2. Heart block greater than first degree, Preexisting bradycardia with Heart rate less than 50. 3.History of Cognitive impairment like dementia, delirium, major stroke. 4.Use of anti-psychotics, antidepressants 5.Kidney or liver disease. 6.Body mass index more than 35 Kilogram per square Meter. 7.Intracranial surgeries. 8.Emergency surgeries.

Design outcomes

Primary

MeasureTime frame
To determine the efficacy of preoperative dexmedetomidine nebulization in reducing the incidence of postoperative deliriumTimepoint: At the end of study duration data will be collected study duration 12 months—

Secondary

MeasureTime frame
To assess the hemodynamical stability including incidence of adverse events such as hypotension and bradycardiaTimepoint: At the end of study duration data will be collected study duration 12 months—

Countries

India

Contacts

Public ContactDr Geetha Muniraju

Fortis Hospital Limited

drgeethachetan@gmail.com8971099794

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026